Investor Presentation - From Farm to Pharma
Perth, July 14, 2015 AEST (ABN Newswire) - PhytoTech Medical Ltd (
ASX:PYL) are pleased to provide an investor presentation titled 'From Farm to Pharma - Unlocking the Medical Cannabis Value Chain'; a science-driven, global approach focused on the medicinal potential of Cannabis and its derivatives.
Executive Summary
Investment Proposition
Poised for rapid and significant growth in the near-term
* MMPR license, cash flow from CBD pill sales and phase 1 clinical trials
Positioned to be dominant player in long-term
* Accelerated entry into new markets via strategic alliances, innovative structuring and an aggressive yet disciplined approach
Significant synergies to be realised from merger
* Complementary strategies and assets; the combined entity collectively has the talent / resources to execute planned initiatives
"Farm to Pharma" is significant competitive advantage
* Strategy not only differentiates but makes possible many aspects of business plan, also serves as huge barrier to entry for competitors
Self Funding Pharmaceutical Developer
* Well timed cash flows from various business lines will enable growth to be financed internally with minimal dilution
Expert board and management team
* Experience across all jurisdictions and operations within the MC value chain
To view the presentation, please visit:
http://media.abnnewswire.net/media/en/docs/ASX-PYL-726262.pdf
About MMJ Group Holdings Ltd
MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: https://www.mmjphytotech.com.au/investors/
| ||
|
